AV 951,
AV-951,
AV951 cpd,
KRN 951,
KRN-951,
KRN951,
tivozanib,
Tivozanib,
475108-18-0,
AV-951,
Tivozanib (AV-951),
KRN-951,
AV 951,
AV951,
KRN951,
KRN 951,
N-[2-CHLORO-4-[(6,7-DIMETHOXY-4-QUINOLYL)OXY]PHENYL]-N'-(5-METHYL-3-ISOXAZOLYL)UREA,
UNII-172030934T,
CHEMBL1289494,
1-(2-Chloro-4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-3-(5-methylisoxazol-3-yl)urea,
1-(2-CHLORO-4-(6,7-DIMETHOXYQUINOLIN-4-YLOXY)PHENYL)-3-(5-METHYLISOXAZOL-3-YL)UREA,
AV-951(Tivozanib),
J-502964,
172030934T,
fotivda,
Kil-8951,
Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor IV,
1-[2-chloro-4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-3-(5-methyl-1,2-oxazol-3-yl)urea,
N-(2-Chloro-4-((6,7-dimethoxy-4-quinolyl)oxy)phenyl)-N′-(5-methyl-3-isoxazolyl)urea,
N-(2-Chloro-4-((6,7-dimethoxy-4-quinolyl)oxy)phenyl)-N'-(5-methyl-3-isoxazolyl)urea,
ASP-4130,
Tivozanib [USAN:INN],
4ase,
KIL8951,
N-{2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl)urea,
AV-951,Tivozanib,
PubChem22421,
Tivozanib(AV-951),
Tivozanib (USAN/INN),
Tivozanib - AV-951,
MLS006011287,
SCHEMBL172883,
GTPL6058,
CHEBI:91327,
KS-00001CTN,
EX-A472,
SYN1013,
SPMVMDHWKHCIDT-UHFFFAOYSA-N,
HMS3229O09,
HMS3244C19,
HMS3244C20,
HMS3244D19,
HMS3265A11,
HMS3265A12,
HMS3265B11,
HMS3265B12,
HMS3654G22,
AOB87139,
BCP01980,
ZINC1489430,
ABP001003,
AN-470,
BDBM50331095,
MFCD15146788,
RS0093,
s1207,
AKOS022177607,
AV951 (KRN951, TIVOZANIB),
BCP9000343,
CCG-206805,
CS-0103,
DB11800,
EX-8600,
KIN0000444,
KRN 951 /TIVOZANIB/AV-951,
PB28569,
NCGC00249390-01,
NCGC00249390-05,
4CA-1259,
AC-24702,
AJ-26332,
AK-41796,
AS-16997,
BC659936,
HY-10977,
SC-54549,
SMR004703037,
AB0007909,
FT-0700315,
ST24037076,
SW219364-1,
X4932,
A24970,
D09683,
Q-3811,
108K180,
BRD-K53414658-001-01-7,
N-[2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]pheny,
AV951, AV-951, 475108-18-0,
1-(2-Chloro-4-((6,7-dimethoxyquinolin-4-yl)-oxy)phenyl)-3-(5-methylisoxazol-3-yl)urea,
1-[2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl]-3-(5-methylisoxazol-3-yl)urea,
1-{2-chloro-4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-3-(5-methyl-1,2-oxazol-3-yl)urea,
N-{2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)-oxy]phenyl}-N'-(5-methyl-3-isoxazolyl)urea,
Urea, N-(2-chloro-4-((6,7-dimethoxy-4-quinolinyl)oxy)phenyl)-N'-(5-methyl-3-isoxazolyl)-,
1-(2-chloro-4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-3-(5-methylisoxazol-3-yl)urea;AV-951,
1-{2-chloro-4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-3-[(3E)-5-methylisoxazol-3(2H)-ylidene]urea,
AV9,
AV951 Tivozanib,
Tivozanib [USAN],
cc-12,
D0W7JZ,
C22H19ClN4O5,
Tivozanib hydrochloride monohydrate,
ASP4130/AV-951,
VEGFR Tyrosine Kinase Inhibitor IV,
ACN-041317,
CID9911830,
A2251,
A10101,
1-[2-chloro-4-(6,7-dimethoxyquinolin-4-yl)oxy-phenyl]-3-(5-methyl-1,2-oxazol-3-yl)urea,